This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Racing Against Time: Covid-19 vs. Vaccines
by Mark Vickery
This past Friday brought the U.S. its largest single-day amount of Covid-19 cases since the pandemic began in earnest back in March of last year: 310K in a single 24-hour period.
BioMarin (BMRN) Reveals 1-Year Data on Hemophilia Gene Therapy
by Zacks Equity Research
BioMarin (BMRN) announces one-year update from GENEr8-1 phase III study, which shows that valoctocogene roxaparvovec significantly reduces annualized bleeding rate (ABR) by 84% in patients with hemophilia A.
What Will Be the Main Economic Drivers in 2021?
by John Blank
With 2020 in the rear-view mirror, we are leaving behind us a plethora of events that affected and shaped our society and economy.
A New Year: Value or Growth? Zacks JAN 2021 Strategy
by John Blank
We had four strong sectors this month, which is bullish. Consumer Discretionary was one of those top areas again this month. COVID has a trifecta of strong spending spots that hit home again. Two internationally exposed sectors -- Materials and Industrials -- also came in at the top, as well.
CureVac (CVAC) Up on Deal With Bayer for COVID-19 Vaccine
by Zacks Equity Research
CureVac (CVAC) gains on a collaboration agreement with Bayer (BAYRY) for further development and supply of its COVID-19 vaccine candidate, CVnCoV.
Pfizer (PFE) Begins Dosing in DMD Study With Gene Therapy
by Zacks Equity Research
Pfizer (PFE) doses the first participant in the phase III CIFFREO study, evaluating its investigational gene therapy, PF-06939926, for treating boys with DMD.
Sarepta (SRPT) Down on Unsatisfactory Data for DMD Candidate
by Zacks Equity Research
Sarepta (SRPT) posts top-line results from part 1 of Study 102, evaluating a single dose of its gene therapy candidate SRP-9001 for treating DMD. Shares fall.
Pharma Stock Roundup: ABBV's Positive Skyrizi Data, AZN, PFE, RHHBY's FDA Updates
by Kinjel Shah
AbbVie's (ABBV) Skyrizi succeeds in psoriatic arthritis and Crohn's disease studies. AstraZeneca (AZN), Pfizer (PFE) and Roche (RHHBY) give FDA updates.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and AstraZeneca
Moderna (MRNA) COVID-19 Vaccine Gets Authorization in Europe
by Zacks Equity Research
Moderna (MRNA) gets conditional use authorization for coronavirus vaccine, mRNA-1273, for use in adults in EU member states.
3 Biotech Technological Developments to Watch Out For in 2021
by Kinjel Shah
Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021
Alexandria (ARE) Prices 6M Share Offering Related to Forward Sale
by Zacks Equity Research
Alexandria (ARE) intends to utilize capital raised from the public offering to fund its pending acquisitions and repay outstanding debt balances.
FDA Opposes Dilution of COVID-19 Vaccine Doses: Here's Why
by Indrajit Bandyopadhyay
The FDA is against any changes to the approved dosing regimens for Pfizer (PFE)/BioNTech (BNTX) and Moderna's (MRNA) coronavirus vaccines as demanded by some experts.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $37.19 in the latest trading session, marking a +1.03% move from the prior day.
Airlines End 2020 on a Solid Note: More Rally Awaited in 2021?
by Maharathi Basu
The availability of vaccines is likely to boost air travel in 2021. As a result, Delta (DAL), American Airlines (AAL), Southwest Airlines (LUV) and United Airlines (UAL) are likely to be aided by the uptick in passenger revenues.
U.S. Dollar Sees First Drop Since 2017: ETFs & Stocks to Buy
by Sweta Killa
The super-easy policies by the Fed and the central government as well as a series of vaccine development have pushed the U.S. dollar down.
Arcturus (ARCT) to Begin Phase II COVID-19 Vaccine Study
by Zacks Equity Research
Arcturus (ARCT) gets FDA's allowance of the IND filing to begin a phase II study on ARCT-021, its COVID-19 vaccine candidate, in the United States. Shares rise.
Pfizer's (PFE) BLA for Somatrogon Gets FDA's Acceptance
by Zacks Equity Research
Pfizer's (PFE) BLA for growth hormone deficiency (GHD) gets accepted by the FDA for standard review. FDA's decision expected in October 2021.
Tech Finishes as the Strongest Sector in 2020
by Zacks Equity Research
Tech Finishes as the Strongest Sector in 2020
Markets Pick Up in 2021 Right Where They Left Off
by Mark Vickery
The Dow is up more than 110 points, the Nasdaq +60 and the S&P 500 +15. It appears there is more appetite at the start of the year to shoot for new all-time highs in the market.
5 Momentum Stocks Bargain Hunters Would Love Chasing
by Nilanjan Choudhury
To tap the market's rally, it will be prudent to invest in momentum stocks that are still cheap. Our choices are Winnebago Industries (WGO), Fiat Chrysler (FCAU), FedEx (FDX), Williams-Sonoma (WSM) and Lennar (LEN).
Top ETF Stories of Fourth-Quarter 2020
by Sanghamitra Saha
The year 2020 as a whole could easily be attributed to the COVID-19 outbreak.
5 Big ETF Stories of 2020 Worth Watching in 2021
by Sweta Killa
We discuss some of the events that dominated the headlines in 2020 and are worth watching in 2021.
Corcept (CORT) Up More Than 50% in Past 3 Months: Here's Why
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
AstraZeneca (AZN) COVID-19 Vaccine Gets Authorization in UK
by Zacks Equity Research
AstraZeneca's (AZN) vaccine for coronavirus receives emergency use approval in the United Kingdom, the first for it anywhere in the world.